


Medical Prognosis Institute A/S



MEDICAL-PROGNOSIS.COM



INVITATION TO SUBSCRIBE FOR **SHARES**

MPI is currently conducting a rights issue of about 12 MSEK, primarily intended to finance the company's further development of the PRP™ platform - a main element in MPI's focus on Personalized Medicine. The rights issue will also finance general operations, taking MPI forward in fulfilling our goals of being a precision medicine company with a remarkable mission to help find personalized cures for cancer.

www.medical-prognosis.com



SEDERMERA
FONDKOMMISSION



CEO PETER BUHL JENSEN'S STATEMENT

Not all Cancer patients benefit from treatment with anti-cancer drugs, but almost every treated patient suffer negative side effects from the treatment they receive. It is very difficult to predict which indication will be helped by a specific drug candidate, and which patient will benefit from treatment. There is a general acceptance for this in the market, and many examples of very expensive anti-cancer drugs being beneficial to only a fraction of the treated patients. The development of anti-cancer drugs and treatments is rapidly changing from having been population-based into being individually tailored, so called Personalized Medicine. MPI's patented DRP™ method makes it possible to identify which patients will respond to a specific treatment. Hereby, the situation can be improved for all concerned: patients, oncologists and drug developers. Instead of treating all patients suffering from a certain type of Cancer, patients are first screened, and only those likely to respond will be treated with the drug candidate in question. With a more well-defined patient population, the likelihood of a successful treatment will increase, while risks and costs decrease. This makes drug development more efficient.

In late 2016, MPI and Oncology Venture - a spinout biotech company from MPI focusing on anti-cancer drug development - entered several agreements that may have significant implications. Three years of exclusivity was agreed upon for OV to utilize MPI's DRP™ technology in anti-cancer drug development. Exclusivity to MPI's DRP™ technology enables OV to increase the number of potential drug candidates to develop, thereby increasing the likelihood of success for the technology. As consideration for the full exclusivity, MPI was granted warrants in OV equalling approximately 3% of the company's total share capital. According to the agreement, OV may also out-license drug development to spinout companies. This enables OV to form companies specializing in for instance women's Cancer, as is the case with recent American spinout company 2X Oncology Inc. Thereby, capital can be attracted from new sources. In such cases, MPI receives a 10% ownership of the spinout company.

A specific DRP biomarker is developed for each drug candidate. This specific DRP™ is used for selecting those patients with the highest likelihood to benefit from treatment with the specific anti-cancer drug. The technology makes it possible to develop new personalized treatments faster and at a lower cost, which is of course beneficial to both Cancer patients and drug developers. OV is currently developing three drugs in eight phase 2 studies. Four of the studies concern the drug LiPlaCis, and are being conducted together with Cadila Pharmaceuticals. In 2X Oncology, a Boston based spinout from OV, the current plan is development of three drugs in four phase 2 studies. A so called Special Purpose Vehicle has been formed in OV-SPV2. Here, the first phase is development of the specific DRP™. If this is successful, two randomized phase 3 studies are planned. These initiatives have taken the DRP technology a long way in drug development, and we are very excited to see the results from the clinical trials. We have good hope for the trials to provide proof-of-concept of the DRP technology, thereby adding significant value to MPI as co-owner of OV and as 10% owner of the spinout companies.

Through MPI's efforts in creating biomarkers for anti-cancer drugs, we realized the same data could be used for developing a product to predict which anti-cancer drugs are likely to be beneficial to the individual patient. We call this product Patient Response Predictor, PRP™. Applying this technology, MPI together with oncologists specialized in Breast Cancer initiated a study. The oncologists got permission to investigate around 800 patients with Metastatic Breast Cancer by analysing their biopsies and comparing the result with the patients' clinical response data. This study greatly accelerated the development of the PRP™,

since published preliminary data show we can predict the individual patient's response to treatment with statistical significance regarding four important drugs used for treating Breast Cancer: epirubicin, fulvestrant, anastasole and examestan. We expect these findings to be of significant importance for PRP™.

The PRP™ technology facilitates a report that can guide the patient and the oncologist in identifying the best treatment for the individual patient.

Utilizing our PRP™ technology will drive development towards Personalized Medicine, thus laying the base for a strong business model for the future. We believe Personalized Medicine will bring a shift in paradigm in the treatment of Cancer patients, and it is our judgement PRP™ puts MPI in the forefront of this development.

The funds from this rights issue will mainly finance MPI's dedicated and ambitious development of the PRP™ platform, which constitutes a key element in our efforts to develop Personalized Medicine.



Peter Buhl Jensen - CEO, Medical Prognosis Institute A/S



mpi PLATFORM



Our Current Focus and The Road Ahead

MPI is focusing on continuously developing the company towards Personalized Medicine. An important part of this focus is the study announced by the company on September 14th, 2016. In collaboration with Breast Cancer experts at Danish oncology departments, MPI is studying patient data from over 800 Metastatic Breast Cancer patients. The aim of the study is to investigate PRP™'s ability to predict whether a patient would respond to anti-cancer treatments given during the disease. Analyses of biopsies from the time of diagnosis render a genetic profile of the patients' tumours. By combining this with clinical response results from hospital charts, we aim to show how the PRP™ tool could predict whether the patients would benefit from different treatments.

Summary of the rights issue

Subscription period: 14 – 29 June 2017

Subscription price/Issue price: SEK 14,80 per share or DKK 11,29 per share.

The scope of the Offer: 814 235 new shares, corresponding to 12 050 678,00 SEK.

Number of shares before the new share issue: 23 612 840 shares.

Record date and preferential rights: The rights issue is conducted with preferential right for existing shareholders in MPI. Record date for receiving subscription rights is the 9th of June 2017. Last trading day in the MPI share with preferential right to participate in the rights issue is the 7th of June 2017. First trading day in the MPI share without preferential right to participate in the rights issue is the 8th of June 2017. For every existing share in MPI on the record date, one (1) subscription right will be received. 29 such subscription rights entitles to subscription of one (1) new share in MPI.

Valuation (pre-money): Approximately 349,5 million SEK.

Trading in the MPI share: The share in MPI is listed on Nasdaq Stockholm First North. Only shares registered in the Euroclear system is subject to trade on Nasdaq Stockholm First North.

ISIN code: DK0060732477

Subscription commitments: MPI has received subscription commitments totaling approximately 6,9 million SEK, about 57,7 % of the total issuance volume. Of the approximately 6,9 million SEK in total subscription commitments, Buhl Krone Holding ApS (co-owned by CEO Peter Buhl Jensen and COO Ulla Hald Buhl) has committed to approximately 1,5 million SEK. Furthermore, Sass & Larsen ApS, a major shareholder in MPI, has committed to approximately 1,3 million SEK.



Motive for the rights issue

The Board of MPI assesses the current capital need in MPI to be about 12 MSEK, corresponding to the size of the current rights issue. The funds from the rights issue is primarily intended to finance MPI's further development of the PRP™ platform - the main element in MPI's focus towards Personalized Medicine. Among other things, this includes financing the study announced the Company on September 14th, 2016. The other main motive for the rights issue is financing daily operations of the Company. Being a company in development phase, MPI currently has a burn rate of about DKK 0.7 - 1 million per month. Like most development companies within the Life Science sector, MPI has limited revenues and are therefor reliant upon risk capital.

MEDICAL PROGNOSIS INSTITUTE A/S **IN SHORT**



Reference to the prospectus and memorandum

All investments in securities are associated with risk. In MPI's prospectus for Danish investors and memorandum for Swedish investors, a description of potential risks associated with the company's business and its shares is presented. Before making an investment decision, these risks together with the other information in the full prospectus or memorandum should be studied thoroughly. The prospectus and memorandum are available at the respective websites of the Company (www.medical-prognosis.com) and Sedermera Fondkommission (www.sedermera.se).



Many anti-cancer drugs are only beneficial to a small group of patients. Cancer patients are treated according to guidelines defined by experience on which treatment has shown to be the most effective. There is currently no way of identifying which patient will respond to a specific treatment. This forces oncologists to treat many patients blindly. If the number of patients responding to a drug is too low, the drug candidate will most likely not be used, even if it may in fact be well suited for certain patients.

MPI was founded in 2004 by Professor Emeritus Steen Knudsen, who has a background within the mathematics of bioinformatics. The MPI approach includes the company's technology Drug Response Predictor (DRP™), for finding the genomic "fingerprint" of each individual tumour. This fingerprint is determined based on sensitivity data from Cancer cell lines. Big data from Cancer patients' biopsies is being used for removing clinically irrelevant signals, i.e. filtering/reducing the background noise. The fingerprint makes it possible to predict whether a patient is likely to benefit from treatment with a certain drug. Per the board's evaluation, MPI's product is a landmark, and can be used both for identifying patients with the best chances of responding to treatment, and for sorting out patients with low likeliness to respond to a certain drug.

Patient Response Prediction (PRP™)

MPI's DRP™ technology is the base of the development of Patient Response Prediction (PRP™). It is the Board's assessment that PRP™ can become a powerful tool for a large group of Cancer patients where other biomarkers are currently unavailable. PRP™ is a business area for innovations within Personalized Medicine, focusing on future development of consumer products and services for informing, gathering and formulating personal treatments. The PRP™ technology makes it possible to assist patients and doctors by helping them determine which treatment is most suitable in each specific case. This will be of great value for patients as well as for the party bearing the treatment costs. MPI has established several co-operations with Danish academies and hospitals for evaluating PRP™ in practise.

"Utilizing our PRP™ technology will drive development towards Personalized Medicine, thus laying the base for a strong business model for the future. We believe Personalized Medicine will bring a shift in paradigm in the treatment of Cancer patients, and it is our judgement PRP™ puts MPI in the forefront of this development."

Peter Buhl Jensen

CEO, Medical Prognosis Institute A/S

Terms and conditions

The offered rights issue

The Board of Directors in Medical Prognosis Institute A/S ("MPI") has on the 1st of June 2017 decided, with authority from the extraordinary general meeting on the 2nd of September 2014, to increase the share capital to a maximum of DKK 40 711.7500. The increase of share capital is carried out by issuance of a maximum of 814,235 new shares with a nominal quota value of DKK 0.0500 each with a subscription price of SEK 14.80 or DKK 11.29 per share. The rights issue is conducted with preferential subscription right for existing shareholders. The general public is offered the possibility to subscribe for shares in the rights issue. Based on the subscription price in SEK the total issue proceeds will add up to a maximum of SEK 12,050,678.00.

Preferential right and subscription rights

Persons and legal entities who were shareholders in MPI on the record date the 9th of June 2017 have preferential right to subscribe for shares in the rights issue in the ratio 29:1, meaning that 29 existing shares gives the right to subscribe for 1 new share.

Existing shareholders preferential right is exercised through subscription rights in which 1 old share entitles to 1 subscription right. 29 such subscription rights entitles to subscription of 1 new share.

Shareholders whose shares were registered in Euroclear Sweden AB ("Euroclear") on the record date receives subscription rights through the Euroclear-system.

Shareholders whose shares were not registered in Euroclear on the record date, receives subscription rights through the VP Securities A/S ("VP-Securities") system.

Subscription price

The subscription price determined by the Board of Directors is SEK 14.80 and the subscription price in DKK is 11.29. The subscription price in DKK is based on the official exchange rate between SEK/DKK at the time of the resolution by the Board of Directors on the 1st of June 2017.

Subscription by payment in DKK is only possible for shareholders whose shares were not registered in the Euroclear-system on the record date and for this reason subscribes by exercising subscription rights issued in the VP-Securities'-system.

Record date

Record date at Euroclear and VP-Securities for participation with preferential rights were the 9th of June 2017. As Nasdaq Stockholm First North is a "T+2 market", the last trading day of shares in MPI including preferential rights were the 7th of June 2017. The first day of trading with shares without preferential rights were the 8th of June 2017.

Subscription period

The subscription period is between the 14th of June 2017 and 29th of June 2017 at 3 pm. After the subscription period, subscription rights not exercised will become invalid and lose their value. Subscription rights not exercised are removed from the shareholders' respective book-entry account in VP-Securities and Euroclear without further notice.

Cross-border transfer of shares in MPI

A cross-border transfer is not possible between the 5th of June 2017 until the 9th of June 2017, both days included, meaning that transfer of shares from VP-Securities to Euroclear or from Euroclear to VP-securities is not possible between the aforementioned period. Subscription rights and subscribed and paid for shares ("BTA") in MPI will not be transferable between VP-Securities and Euroclear or from Euroclear to VP-Securities.

Trading with subscription rights

Only subscription rights issued through the Euroclear-system will be tradeable on Nasdaq Stockholm First North during the subscription period. Trading with subscription rights takes place from the 14th of June 2017 until 27th of June 2017 (both days included) on Nasdaq Stockholm First North. Shareholders must contact their bank or broker with the required authority to conduct trading of subscription rights.

Subscription rights acquired during the aforementioned trading period provides, during the subscription period, the same preferential right to subscribe for new shares, as allotted subscription rights based on the individual shareholder's shareholding in MPI as per the record date. Subscription rights must be exercised no later than the 29th of June 2017 or sold no later than the 27th of June 2017, in order to not become of no value.

Preprinted paying slips and subscription forms

Shareholders with preferential rights

Shareholders or representatives of shareholders, who on the record date, the 9th of June 2017, were registered in the Euroclear-system, receives a preprinted paying slip (account statement), the subscription form "Subscription with subscription rights", the subscription form "Subscription without subscription rights" and a folder containing the terms and conditions for the rights issue with referral to the investment memorandum. The information can be downloaded at Sedermera Fondkommission's web page (www.sedermera.se), or at the web page of MPI (www.medical-prognosis.com). Shareholders who are included in the separate list of pledgees and others in relation to the Euroclear-system, do not receive information and will be notified separately. An account notice, which declares the delivery of subscription rights on the shareholders' book-entry account, are not distributed.

Shareholders or representatives of shareholders, who on the record date, the 9th of June 2017, were only registered in VP-Securities-system will not receive any printed information.

Information and investment memorandum will be available on Sedermera Fondkommission's web page (www.sedermera.se) and the web page of MPI (www.medical-prognosis.com) for download. Shareholders who are included in the separate list of pledgees and others in relation to VP-Securities-system do not receive information and will be notified separately. An account notice, which declares the delivery of subscription rights on the shareholders' book-entry account, are not distributed.

Subscription of shares with preferential right through Euroclear

Subscription of shares with preferential rights for those shareholders who on the record date were registered in the Euroclear-system shall be carried out by simultaneous payment in SEK no later than the 29th of June 2017 at 3 pm. Subscription of shares by payment of the subscription amount must be carried out either by the use of the preprinted paying slip, or by the payment instructions on the subscription form "Subscription with subscription rights" in accordance with the following:

1) Preprinted paying slip (account statement).

If all subscription rights allotted on the record date are exercised, only the preprinted paying slip shall be used as documentation for subscription by way of cash payment. The subscription form "Subscription with subscription rights" shall not be used in this case.

2) Subscription form – "Subscription with subscription rights"

In the event that another amount of subscription rights, than what is stated on the preprinted paying slip, is exercised for subscription (e.g. due to subscription rights being acquired or sold) the subscription form "Subscription with subscription rights" shall be used as basis for subscription by way of cash payment. The shareholder must specify on the subscription form the amount of subscription rights being exercised, number of shares subscribed for and the amount in SEK to be paid. If payment is made any other way than by the payment instructions on the subscription form, the VP-account (an owner-registered account in Euroclear) must be indicated as payment reference. An incomplete or faulty subscription form may not be taken into consideration. The subscription form "Subscription with subscription rights" can be obtained by calling Sedermera Fondkommission on the phone number stated below. A completed subscription form must, in connection with cash payment, be sent or faxed to, and received by, Sedermera Fondkommission no later than the 29th of June 2017 at 3 pm on the contact details stated below. The subscription is binding.

Sedermera Fondkommission

Subject: MPI

Norra Vallgatan 64, 211 22 Malmö, Sweden

Fax: +46 (0) 40-615 14 1, Phone: +46 (0) 40-615 14 10

E-mail: nyemission@sedermera.se (scanned subscription form)

Subscription of shares with preferential right through VP-Securities

Subscription and payment of shares with preferential rights for shareholders who, on the record date, were only registered in VP-Securities, and thus not registered in Euroclear, shall be carried out according to instructions from each account-holding bank or broker registered in VP-Securities no later than the 29th of June 2017 at 3 pm. Payment shall be made in DKK.

Nominee-registered shareholders

Shareholders whose shares in MPI were nominee-registered through a bank or broker will not receive preprinted paying slips or subscription forms. However, shareholders who, on the record date, were nominee-registered in the Euroclear-system, receive a folder containing the terms and conditions for the rights issue with referral to the investment memorandum. Subscription and payment shall be carried out according to instructions from each account-holding bank or broker.

Subscription without preferential right

It is only possible to apply for subscription of shares without preferential right in SEK. Request for subscription shall be made on the subscription form "Subscription without subscription rights" which can be downloaded from Sedermera Fondkommission's web page (www.sedermera.se) and the web page of MPI (www.medical-prognosis.com).

Nominee-registered shareholders, requesting subscription of shares without preferential right, must coordinate such a subscription with the account-holding bank or broker in accordance with instructions from the respective account-holding bank or broker, or if shares are registered at several different nominee-registered accounts, from each of these account-holding banks or brokers. Note that shareholders or other investors who have an account with specific rules for securities transactions, such as an investment savings account (Swedish: Investeringsparkonto) or endowment account (Swedish: Kapitalförsäkring), must check with the account-holding bank or broker, whether, and if so, how the subscription of shares in the rights issue is possible. The subscription shall, in that case be made in accordance with instructions received from the account-holding bank or broker.

An incomplete or faulty subscription form "Subscription without subscription rights" may not be taken into consideration. It is only allowed to submit one (1) subscription form "Subscription without subscription rights". If more than one subscription form is sent, only the last subscription form received will be considered as valid. The subscription form must be Sedermera Fondkommission at hand no later than the 29th of June 2017 at 3 pm. The subscription is binding.

Allocation of shares subscribed for without preferential right

In the event that not all shares in the rights issue are subscribed for with preferential right, the Board of Directors shall decide on allocation of shares within the limits of the maximum amount of the rights issue to shareholders or other investors that have subscribed for shares without preferential right.

Primarily; allocation of shares which are subscribed for without preferential right shall be done to shareholders or other investors who have also subscribed for new shares by exercising subscription rights, regardless if the subscriber was a registered shareholder on the record date or not. In case that allocation of shares cannot fully be provided in accordance to subscriptions without subscription rights, allocation shall be made in relation (pro rata) to the quantity of subscription rights exercised for subscription of new shares in the rights issue, and to the extent this is not possible, by drawing of lots.

Subsequently; allocation of shares which are subscribed for without preferential right shall be done to other investors than the above mentioned, who have subscribed for shares without subscription rights. In case that allocation of shares cannot fully be provided in accordance to subscriptions without subscription rights, allocation shall be made in relation (pro rata) to the amount of subscribed for shares without subscription rights in the rights issue, and to the extent this is not possible, by drawing of lots.

Notification of allotment of shares without preferential rights will be made via a contract note containing payment instructions for allotted shares. Contract notes are expected to be sent out as soon as possible after the subscription period, and payment must be made in SEK in accordance with the payment instructions on the contract note. Payment is due within four Swedish business days from the date the contract note was distributed. Note that payment for any allotted shares will not be drawn from the specified book-entry account. If payment is not received in due time, the subscribed for shares may be assigned to another party. Should the price by such an assignment be lower than the subscription price of the rights issue, the subscriber who initially was allocated these shares may vouch for all or a part of the difference. Shareholders or other investors that are not allotted any shares will not receive any notification.

Shareholders residing outside of Denmark and Sweden

Shareholders who reside outside of Denmark and Sweden (with the exception of shareholders residing in USA, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore and other countries in which participation in the rights issue requires supplementary prospectus, further registration or other measurements than those which are required by Danish and Swedish legislation) who have preferential right in the rights issue can contact Sedermera Fondkommission for further information about subscription and payment. Due to restrictions in the legislation regarding securities in USA, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore and other countries in which participation requires supplementary prospectus, further registration or other measurements than those which are required by Danish and Swedish legislation, subscription rights through Euroclear will not be issued to shareholders with registered addresses in any of these countries. Accordingly, no offer is made to subscribe for shares in MPI to shareholders residing in these countries.

Shareholders and investors residing in Denmark or other countries outside of Sweden

Shareholders and other investors residing in Denmark or other countries outside of Sweden who can subscribe for shares in the rights issue are notified that subscription and payment of shares through a non-Swedish bank or broker might be associated with additional costs or fees which will be charged the shareholder or investor by the specific bank or broker. Furthermore, delivery and account-holding of shares via a non-Swedish bank or broker may be associated with additional costs or fees, which will be charged the shareholder or investor by the specific bank or broker.

BTA's - Paid and subscribed for shares

Subscription through payment is registered in Euroclear and VP Securities as soon as possible after payment, normally a couple of business days after payment has been made. Subscribers who have subscribed and paid in the Euroclear-system will subsequently receive an account notice from Euroclear which confirms the delivery of BTA's to the subscribers book-entry account. Subscribed and paid for shares are registered as BTA's in book-entry accounts in Euroclear and VP-Securities until the rights issue has been registered at the Danish Business Authority. In case that a partial registration of the rights issue is conducted, several series of BTA's will be issued in the Euroclear-system, where the first series of BTA's will be labeled "BTA 1". The series of BTA 1 will, together with BTA's subscribed for with preferential right within the VP-Securities-system, be converted into shares as soon as a partial registration by the Danish Business Authority has taken place. A subsequent series of BTA, labeled "BTA 2", will be issued in the Euroclear-system for subscriptions which due to time-related matters could not be registered together with the series of BTA 1, and the series of BTA 2 will be converted to shares as soon as possible upon final registration of the rights issue with the Danish Business Authority. BTA's are registered on book-entry accounts in Euroclear and VP-Securities until the rights issue is registered by the Danish Business Authority, which is expected to take place at the end of July 2017. Shareholders or other investors, whose shares are nominee-registered through a bank or broker, will obtain information from each such bank or broker.

Trading in BTA's

Only BTA's issued through the Euroclear-system will be tradeable on Nasdaq Stockholm First North. Trading in BTA's will take place on Nasdaq Stockholm First North from the 14th of June 2017 until the rights issue is registered at the Danish Business Authority. In case that a partial registration of the rights issue is conducted, and several series of BTA's are issued in the Euroclear-system, the different series of BTA's may be traded simultaneously on Nasdaq Stockholm First North. However, BTA 2 may not be listed for trading on Nasdaq Stockholm First North.

Information regarding delivery and registration of shares

Since MPI is a Danish public limited liability company, all of the company's shares are issued through, and hence registered in, the VP-Securities system. In order to trade the shares on Nasdaq Stockholm First North, clearing need to occur within the Euroclear-system which means that the shares must be registered in Euroclear. All shares registered in Sweden are mirrored in the Euroclear-system from VP-Securities. This means that Euroclear is registered

as owner of the shares on behalf of underlying shareholders, in the shareholder register kept by VP-Securities.

Shares which are subscribed for on basis of preferential right, by exercising subscription rights issued in the VP-Securities-system, and which are paid for in DKK, will not be registered in Euroclear and will hence not be tradeable on Nasdaq Stockholm First North. In order for such shares to be tradeable on Nasdaq Stockholm First North, the shareholder must first administrate a cross-border transfer of shares to Euroclear. Such a cross-border transfer of shares may be subject to additional costs or fees, which will be charged the shareholder or investor by the specific account holding bank or broker.

Shares which are subscribed for without preferential rights and paid for in SEK, will be delivered to investors through the Euroclear-system and will hence be tradeable on Nasdaq Stockholm First North.

As soon as the rights issue has been registered at the Danish Business Authority, as expected in week 29 2017, BTA's are converted into shares without further notice from Euroclear and VP-Securities. Partial registration of shares in the rights issue may occur at the Danish Business Authority.

Publication of the result of the rights issue

As soon as possible after the subscription period, MPI will publish the result of the rights issue through a press release.

Applicable legislation

The shares are issued pursuant to the Danish Companies Act and are governed by Danish legislation. MPI is governed by Swedish legislation in certain aspects.

Right to dividend

The new shares entail the right to any dividend for the first time on the first record date of dividend which occurs after the new shares are registered at the Danish Business Authority. The new shares carry the same right to dividend as existing shares. Payment of any dividend for shares registered in the Euroclear-system is managed by Euroclear, or for nominee-registered shares, in accordance with the respective account-holding bank or brokers' routines. Payment of any dividend for shares only registered in the VP-Securities-system is managed by VP-Securities. Payment of any dividend will be made in DKK. Payment of any dividend for shares registered in the Euroclear-system will be made in SEK after exchange by either MPI or Euroclear. See section "Dividend and voting rights etc."

Register of shareholders

MPI's shareholder register is handled and administrated partly by VP-Securities and partly by Euroclear.

Shareholder rights

The shareholders' right to dividend, voting right, preferential right of shares is governed by both MPI's articles of association (available via the web page of MPI and in the investment memorandum), as well as the Danish Companies Act. The Swedish Companies Act applies in relevant aspects, e.g. as regards to the rules on certain related transactions. See section "Transactions with Related Parties".

Shareholder obligation to report shareholdings

All shareholders in MPI has an obligation to comply with the rules of reporting to the Public Register of Shareholders. Report of shareholdings shall be made to MPI (nla@medical-prognosis.com) within 14 days after the obligation to report has been triggered. Obligation to report is triggered when shareholdings in MPI crosses the thresholds of 5, 10, 15, 20, 25, 50, 90, 100 %, 1/3 or 2/3.

See https://erhvervsstyrelsen.dk/sites/default/files/vejledning_det_offentlige_ejerregister.pdf for more information regarding reporting obligations to the Public Register of Shareholders.

Trading in the MPI share

The shares of MPI are listed on Nasdaq Stockholm First North. The shares are traded under the symbol "MPI" and have the ISIN-code DK0060732477. Only shares that are affiliated to Euroclear are, and will be, tradeable on Nasdaq Stockholm First North. New issued shares which are delivered through the Euroclear-system are tradeable in conjunction with the conversion of BTA's to shares in the Euroclear's system.

Issuing agents in the rights issue

Sedermera Fondkommission is the issuing agent of MPI in Sweden. Danske Bank A/S is the issuing agent of MPI in Denmark.

Other

The Board of Directors in MPI reserves the right to extend the subscription period and the payment deadline in the rights issue. The subscription of new shares with or without preferential right are binding.

In the case an excess amount has been paid by a subscriber for the new shares, the excess amount will be repaid to the subscriber. Excess amounts less than 100 SEK or 100 DKK will not be refunded.

Questions regarding the rights issue may be directed to:

Medical Prognosis Institute A/S	Sedermera Fondkommission
Phone: +45 40 14 50 59	Phone: +46 (0)40-615 14 10
E-mail: nla@medical-prognosis.com	E-mail: nyemission@sedermera.se